864 related articles for article (PubMed ID: 8671483)
21. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
22. Oestrogen treatment for increased bleeding in Norplant users: preliminary results.
Witjaksono J; Lau TM; Affandi B; Rogers PA
Hum Reprod; 1996 Oct; 11 Suppl 2():109-14. PubMed ID: 8982752
[TBL] [Abstract][Full Text] [Related]
23. A longitudinal study of changes in endometrial microvascular density in Norplant implant users.
Hickey M; Simbar M; Young L; Markham R; Russell P; Fraser IS
Contraception; 1999 Feb; 59(2):123-9. PubMed ID: 10361627
[TBL] [Abstract][Full Text] [Related]
24. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
Mascarenhas L; van Beek A; Bennink HC; Newton J
Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
[TBL] [Abstract][Full Text] [Related]
25. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
26. A review of the endometrial changes in Norplant users.
Wan LS
Ann N Y Acad Sci; 1997 Sep; 828():108-10. PubMed ID: 9329828
[TBL] [Abstract][Full Text] [Related]
27. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
Fleming D; Davie J; Glasier A
Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
[TBL] [Abstract][Full Text] [Related]
28. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
[TBL] [Abstract][Full Text] [Related]
29. Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding.
Hickey M; Fraser IS
Hum Reprod; 2002 Sep; 17(9):2428-34. PubMed ID: 12202436
[TBL] [Abstract][Full Text] [Related]
30. Menstrual bleeding patterns in Norplant-2 implant users.
Biswas A; Leong WP; Ratnam SS; Viegas OA
Contraception; 1996 Aug; 54(2):91-5. PubMed ID: 8842585
[TBL] [Abstract][Full Text] [Related]
31. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism?
Mandelin E; Koistinen H; Koistinen R; Affandi B; Seppälä M
Hum Reprod; 1997 Dec; 12(12):2671-5. PubMed ID: 9455833
[TBL] [Abstract][Full Text] [Related]
32. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
Kaewrudee S; Taneepanichskul S; Jaisamraun U; Reinprayoon D
Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
[TBL] [Abstract][Full Text] [Related]
33. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
34. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
35. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ.
Gu Z; Zhu P; Luo H; Zhu X; Zhang G; Wu S
Contraception; 1995 Jul; 52(1):57-61. PubMed ID: 8521716
[TBL] [Abstract][Full Text] [Related]
36. NORPLANT and the levonorgestrel IUD in Chinese family planning programmes.
Xiao BL; Gu SJ; Wang SL; Zhu PD; Shi SQ
Ann Med; 1993 Apr; 25(2):161-5. PubMed ID: 8489754
[TBL] [Abstract][Full Text] [Related]
37. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users.
Marbaix E; Vekemans M; Galant C; Rigot V; Lemoine P; Dubois D; Picquet C; Henriet P; Twagirayezu P; Sufi S; Eeckhout Y; Courtoy PJ
Hum Reprod; 2000 Aug; 15 Suppl 3():120-34. PubMed ID: 11041228
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding.
Chegini N; Rhoton-Vlasak A; Williams RS
Fertil Steril; 2003 Sep; 80(3):564-70. PubMed ID: 12969699
[TBL] [Abstract][Full Text] [Related]
39. Angiogenic effects of norplant contraception on endometrial histology and uterine bleeding.
Pritts EA; Ryan IP; Mueller MD; Lebovic DI; Shifren JL; Zaloudek CJ; Korn AP; Darney PD; Taylor RN
J Clin Endocrinol Metab; 2005 Apr; 90(4):2142-7. PubMed ID: 15623808
[TBL] [Abstract][Full Text] [Related]
40. Endometrial morphological changes in IUD users: a review.
Sheppard BL
Contraception; 1987 Jul; 36(1):1-10. PubMed ID: 3117492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
